Key facts
- This page summarizes Edward Clouston MacPherson's Form 4 filing for Telomir Pharmaceuticals, Inc. (TELO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 May 2026, 20:00.
Edward Clouston MacPherson - 21 May 2026 Form 4 Insider Report for Telomir Pharmaceuticals, Inc. (TELO)
- Reporting relationship
- Director
- Issuer ticker
- TELO
- Reported as of
- 21 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 May 2026, 20:00:19 UTC
- Prior SEC filing
- 10 Dec 2024
- Next SEC filing
- 15 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ned MacPherson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Edward Clouston MacPherson filed Form 4 for Telomir Pharmaceuticals, Inc. (TELO) on 22 May 2026.
Change
- Previous filing in this sequence was filed on 10 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002015989
Primary reporting owner
MacPherson Edward Clouston
- Relationship
- Director
- Address
- C/O TELOMIR PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, MIAMI
- Signature
- /s/ Ned MacPherson
- Signature date
- 22 May 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TELO
transaction
Derivative
Incentive Stock Options (right to buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- Shares after
- 25,000
- Date
- 21 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $1.30
- Footnotes
- F1, F2
TELO
transaction
Derivative
Incentive Stock Options (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 21 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $5.02
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The options are fully exercisable.
Footnote F2
The reporting person agreed to cancellation of the option granted to him on 08/27/2024, in exchange for a new option having a lower exercise price.